10,736 results match your criteria Ovarian Cancer* Obstetrics and Gynecology


Factors associated with referral and completion of genetic counseling in women with epithelial ovarian cancer.

Int J Gynecol Cancer 2020 May 23. Epub 2020 May 23.

Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Objective: The National Comprehensive Cancer Network recommends that all women diagnosed with epithelial ovarian cancer undergo genetic testing, as the diagnosis of pathogenic variants may inform cancer survival and impact treatment options. The objective of this study was to assess factors associated with referral to genetic counseling in women with epithelial ovarian cancer.

Methods: A retrospective cohort study identified women with epithelial ovarian cancer from 2012 to 2017 at Massachusetts General Hospital and North Shore Medical Center, a community hospital affiliated with Massachusetts General Hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2019-001168DOI Listing

Frontline fighters: the continued fight against COVID-19.

Int J Gynecol Cancer 2020 May 23. Epub 2020 May 23.

Gynecology and Obstetrics, Division of Gynecologic Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001534DOI Listing

Exploring the potential of engineered exosomes as delivery systems for tumor-suppressor microRNA replacement therapy in ovarian cancer.

Biochem Biophys Res Commun 2020 Jun 28;527(1):153-161. Epub 2020 Apr 28.

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 5650871, Japan.

MicroRNA (miRNA) plays a pivotal role in cancer biology. Therefore, tumor suppressor (TS) miRNAs are an attractive target for cancer therapy. However, clinical trials have failed due to the difficulties in miRNA delivery, warranting the development of a novel drug delivery system (DDS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2020.04.076DOI Listing

Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses.

J Appl Lab Med 2020 Mar;5(2):263-272

Institute of Biomedicine, Research Center for Cancer, Infections and Immunity, Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.

Background: The cancer antigen 125 (CA125) immunoassay (IA) does not distinguish epithelial ovarian cancer (EOC) from benign disease with the sensitivity needed in clinical practice. In recent studies, glycoforms of CA125 have shown potential as biomarkers in EOC. Here, we assessed the diagnostic abilities of two recently developed CA125 glycoform assays for patients with a pelvic mass. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jalm/jfz012DOI Listing

Palliative treatment for bowel obstruction in ovarian cancer: a meta-analysis.

Arch Gynecol Obstet 2020 May 22. Epub 2020 May 22.

Department of Obstetrics and Gynecology, First Affiliated Hospital of Soochow University, 899 Pinghai Road, SuzhouSuzhou, 215006, Jiangsu, China.

Objective: To comprehensively evaluate and compare outcomes of surgical versus nonsurgical palliative interventions for bowel obstruction due to ovarian cancer.

Methods: Studies were obtained from database search systems of Pubmed, Medline, Wiley, Springerlink, Kluwer, Web of science and Science direct. Data were analyzed by the meta-analysis method and the random-effect or fixed-effect model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-020-05545-yDOI Listing

The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes.

Sci Rep 2020 May 22;10(1):8558. Epub 2020 May 22.

Women and Infants Hospital, Department of Obstetrics and Gynecology, Program in Women's Oncology, Providence, RI, USA.

Epithelial ovarian cancer (EOC) is a highly lethal gynecologic malignancy arising from the fallopian tubes that has a high rate of chemoresistant recurrence and low five-year survival rate. The ovarian cancer biomarker HE4 is known to promote proliferation, metastasis, chemoresistance, and suppression of cytotoxic lymphocytes. In this study, we sought to examine the effects of HE4 on signaling within diverse cell types that compose the tumor microenvironment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-65353-xDOI Listing

Comparisons of Clinical Outcomes in Women with Advanced Ovarian Cancer Treated with Frontline Intraperitoneal versus Dose-Dense Platinum/Paclitaxel Chemotherapy without Bevacizumab.

Int J Environ Res Public Health 2020 May 20;17(10). Epub 2020 May 20.

Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan.

We aimed to compare the clinical outcomes between intraperitoneal chemotherapy and dose-dense chemotherapy for the frontline treatment of advanced ovarian, fallopian tube and primary peritoneal cancer in women not receiving bevacizumab. All consecutive women with stage II~IV cancer treated with either frontline intraperitoneal or dose-dense platinum/paclitaxel chemotherapy and not receiving bevacizumab between March 2006 and June 2019 were reviewed. A total of 50 women (intraperitoneal group, = 22; dose-dense group, = 28) were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijerph17103603DOI Listing

Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare.

Cancers (Basel) 2020 May 20;12(5). Epub 2020 May 20.

Predictive, Preventive and Personalised (3P) Medicine, Department of Radiation Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, 53113 Bonn, Germany.

Rho guanosine triphospatases (GTPases) resemble a conserved family of GTP-binding proteins regulating actin cytoskeleton dynamics and several signaling pathways central for the cell. Rho GTPases create a so-called Ras-superfamily of GTPases subdivided into subgroups comprising at least 20 members. Rho GTPases play a key regulatory role in gene expression, cell cycle control and proliferation, epithelial cell polarity, cell migration, survival, and apoptosis, among others. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12051292DOI Listing

Sulforaphane enhances the cisplatin sensitivity through regulating DNA repair and accumulation of intracellular cisplatin in ovarian cancer cells.

Exp Cell Res 2020 May 10:112061. Epub 2020 May 10.

Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, China. Electronic address:

Objectives: Cisplatin is commonly applied as anticancer agent for various cancers, including ovarian cancer. Unfortunately, the drug resistance frequently occurred which obstructing the effect of cisplatin on tumors. The goal of our research was to investigate the reversal actions and the potential mechanisms of sulforaphane (SFN) on cisplatin resistance in ovarian carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2020.112061DOI Listing

EZH2/H3K27Me3 and phosphorylated EZH2 predict chemotherapy response and prognosis in ovarian cancer.

PeerJ 2020 12;8:e9052. Epub 2020 May 12.

Department of Gynecology and Obstetrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Background: EZH2 acts as an oncogene through canonical pathway EZH2/H3K27Me3 and uncanonical pathway pAkt1/pS21EZH2 in many solid tumors including ovarian cancer. However, the clinical value of EZH2/H3K27Me3 and pAkt1/pS21EZH2 remain unclear. In the current study, we aim to investigate the correlation between these two pathways to clinical-pathological parameters and prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7717/peerj.9052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227641PMC

Tetrandrine Reverses Paclitaxel Resistance in Human Ovarian Cancer via Inducing Apoptosis, Cell Cycle Arrest Through β-Catenin Pathway.

Authors:
Luo Jiang Rui Hou

Onco Targets Ther 2020 30;13:3631-3639. Epub 2020 Apr 30.

Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, People's Republic of China.

Background: Paclitaxel (PTX) resistance is a great obstacle for the treatment of ovarian cancer. A previous study indicated that tetrandrine (TET) could induce the apoptosis of ovarian cancer cells. This study aimed to explore the effect of TET in combination with PTX on PTX resistance in ovarian cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S235533DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200223PMC

M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis.

Cells 2020 May 15;9(5). Epub 2020 May 15.

Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany.

Multi drug resistance protein 1 (MDR1) expression on tumor cells has been widely investigated in context of drug resistance. However, the role of MDR1 on the immune cell infiltrate of solid tumors remains unknown. The aim of this study was to analyze the prognostic significance of a MDR1+ immune cell infiltrate in epithelial ovarian cancer (EOC) and to identify the MDR1+ leucocyte subpopulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells9051224DOI Listing

IGF1R Axis Inhibition Restores Dendritic Cell Antitumor Response in Ovarian Cancer.

Transl Oncol 2020 May 16;13(8):100790. Epub 2020 May 16.

Gynecology Laboratory, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy. The insulin-like growth factor (IGF) system plays a key role in regulating growth and invasiveness in several malignancies, including ovarian cancer. IGF1R targeting showed antiproliferative activity of EOC cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2020.100790DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232112PMC

Ovarian cancer-excreted exosomal miR-199a-5p suppresses tumor metastasis by targeting hypoxia-inducible factor-2α in hypoxia microenvironment.

Cancer Commun (Lond) 2020 May 19. Epub 2020 May 19.

Department of Pathology, the First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, 250014, P. R. China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cac2.12034DOI Listing

Bowel Perforation in the Emergency Department Related to Bevacizumab Therapy and Recurrent Ovarian Cancer.

Clin Pract Cases Emerg Med 2020 May 27;4(2):227-229. Epub 2020 Mar 27.

University of Alabama at Birmingham, Department of Emergency Medicine, Birmingham, Alabama.

Case Presentation: We describe the presentation to the emergency department of a patient with recurrent ovarian cancer treated with bevacizumab with the complication of bowel perforation.

Discussion: We review the frequency and outcomes of bevacizumab-related bowel perforation. We also report the patient's imaging findings, including the radiologic presentation of free intraperitoneal air and portal venous gas, both indicative of bowel perforation and the need for emergent surgical evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5811/cpcem.2020.1.45374DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219984PMC

Circular RNA Circ_0025033 Promotes the Evolvement of Ovarian Cancer Through the Regulation of miR-330-5p/KLK4 Axis.

Cancer Manag Res 2020 23;12:2753-2765. Epub 2020 Apr 23.

Henan Medical School, Henan University, Kaifeng, Henan, People's Republic of China.

Background: Circular RNAs (circRNAs) are significant molecular targets in various types of human cancers. The functional mechanism of circRNA_0025033 (circ_0025033) in ovarian cancer (OC) was discussed in the current report.

Methods: The quantitative real-time polymerase chain reaction (qRT-PCR) was used for determining the circ_0025033 and microRNA-330-5p (miR-330-5p) levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S241372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186775PMC

Phosphoproteomics Reveals Key Regulatory Kinases and Modulated Pathways Associated with Ovarian Cancer Tumors.

Onco Targets Ther 2020 29;13:3595-3605. Epub 2020 Apr 29.

Jiangxi Provincial Key Laboratory of Translational Medicine and Oncology, Jiangxi Cancer Hospital, Jiangxi Cancer Center, Nanchang 330029, People's Republic of China.

Background: Ovarian cancer (OC) is the seventh most common cancer worldwide for women. However, there are no sufficient diagnostic methods and few treatment options available due to poor understanding of its pathogenic mechanisms.

Methods: To comprehensively analyze the phosphoproteomic characterization for OC, we took advantage of a quantitative global phosphoproteomics method, titanium(IV) immobilized metal affinity chromatography (Ti-IMAC) coupled to nanoscale liquid chromatography and quadrupole time-of-flight tandem mass spectrometry (nanoLC/Q-TOF-MS/MS) on ovarian tissue samples obtained from five OC patients and five matched controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S240164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196812PMC

DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.

Authors:
Nan Ma Yuqing Zhao

Cell Biochem Funct 2020 May 19. Epub 2020 May 19.

Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.

Ovarian cancer (OC) is one of the most common gynaecologic malignancies. Deleted in malignant brain tumors 1 (DMBT1) was considered as a tumour suppressor in multiple cancers, but there have been no systemic profiling studies of DMBT1 in OC until now. The aim of this study is to explore the role and the potential mechanism of DMBT1 in OC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cbf.3549DOI Listing

Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.

Authors:
Haoyu Zhang Thomas U Ahearn Julie Lecarpentier Daniel Barnes Jonathan Beesley Guanghao Qi Xia Jiang Tracy A O'Mara Ni Zhao Manjeet K Bolla Alison M Dunning Joe Dennis Qin Wang Zumuruda Abu Ful Kristiina Aittomäki Irene L Andrulis Hoda Anton-Culver Volker Arndt Kristan J Aronson Banu K Arun Paul L Auer Jacopo Azzollini Daniel Barrowdale Heiko Becher Matthias W Beckmann Sabine Behrens Javier Benitez Marina Bermisheva Katarzyna Bialkowska Ana Blanco Carl Blomqvist Natalia V Bogdanova Stig E Bojesen Bernardo Bonanni Davide Bondavalli Ake Borg Hiltrud Brauch Hermann Brenner Ignacio Briceno Annegien Broeks Sara Y Brucker Thomas Brüning Barbara Burwinkel Saundra S Buys Helen Byers Trinidad Caldés Maria A Caligo Mariarosaria Calvello Daniele Campa Jose E Castelao Jenny Chang-Claude Stephen J Chanock Melissa Christiaens Hans Christiansen Wendy K Chung Kathleen B M Claes Christine L Clarke Sten Cornelissen Fergus J Couch Angela Cox Simon S Cross Kamila Czene Mary B Daly Peter Devilee Orland Diez Susan M Domchek Thilo Dörk Miriam Dwek Diana M Eccles Arif B Ekici D Gareth Evans Peter A Fasching Jonine Figueroa Lenka Foretova Florentia Fostira Eitan Friedman Debra Frost Manuela Gago-Dominguez Susan M Gapstur Judy Garber José A García-Sáenz Mia M Gaudet Simon A Gayther Graham G Giles Andrew K Godwin Mark S Goldberg David E Goldgar Anna González-Neira Mark H Greene Jacek Gronwald Pascal Guénel Lothar Häberle Eric Hahnen Christopher A Haiman Christopher R Hake Per Hall Ute Hamann Elaine F Harkness Bernadette A M Heemskerk-Gerritsen Peter Hillemanns Frans B L Hogervorst Bernd Holleczek Antoinette Hollestelle Maartje J Hooning Robert N Hoover John L Hopper Anthony Howell Hanna Huebner Peter J Hulick Evgeny N Imyanitov Claudine Isaacs Louise Izatt Agnes Jager Milena Jakimovska Anna Jakubowska Paul James Ramunas Janavicius Wolfgang Janni Esther M John Michael E Jones Audrey Jung Rudolf Kaaks Pooja Middha Kapoor Beth Y Karlan Renske Keeman Sofia Khan Elza Khusnutdinova Cari M Kitahara Yon-Dschun Ko Irene Konstantopoulou Linetta B Koppert Stella Koutros Vessela N Kristensen Anne-Vibeke Laenkholm Diether Lambrechts Susanna C Larsson Pierre Laurent-Puig Conxi Lazaro Emilija Lazarova Flavio Lejbkowicz Goska Leslie Fabienne Lesueur Annika Lindblom Jolanta Lissowska Wing-Yee Lo Jennifer T Loud Jan Lubinski Alicja Lukomska Robert J MacInnis Arto Mannermaa Mehdi Manoochehri Siranoush Manoukian Sara Margolin Maria Elena Martinez Laura Matricardi Lesley McGuffog Catriona McLean Noura Mebirouk Alfons Meindl Usha Menon Austin Miller Elvira Mingazheva Marco Montagna Anna Marie Mulligan Claire Mulot Taru A Muranen Katherine L Nathanson Susan L Neuhausen Heli Nevanlinna Patrick Neven William G Newman Finn C Nielsen Liene Nikitina-Zake Jesse Nodora Kenneth Offit Edith Olah Olufunmilayo I Olopade Håkan Olsson Nick Orr Laura Papi Janos Papp Tjoung-Won Park-Simon Michael T Parsons Bernard Peissel Ana Peixoto Beth Peshkin Paolo Peterlongo Julian Peto Kelly-Anne Phillips Marion Piedmonte Dijana Plaseska-Karanfilska Karolina Prajzendanc Ross Prentice Darya Prokofyeva Brigitte Rack Paolo Radice Susan J Ramus Johanna Rantala Muhammad U Rashid Gad Rennert Hedy S Rennert Harvey A Risch Atocha Romero Matti A Rookus Matthias Rübner Thomas Rüdiger Emmanouil Saloustros Sarah Sampson Dale P Sandler Elinor J Sawyer Maren T Scheuner Rita K Schmutzler Andreas Schneeweiss Minouk J Schoemaker Ben Schöttker Peter Schürmann Leigha Senter Priyanka Sharma Mark E Sherman Xiao-Ou Shu Christian F Singer Snezhana Smichkoska Penny Soucy Melissa C Southey John J Spinelli Jennifer Stone Dominique Stoppa-Lyonnet Anthony J Swerdlow Csilla I Szabo Rulla M Tamimi William J Tapper Jack A Taylor Manuel R Teixeira MaryBeth Terry Mads Thomassen Darcy L Thull Marc Tischkowitz Amanda E Toland Rob A E M Tollenaar Ian Tomlinson Diana Torres Melissa A Troester Thérèse Truong Nadine Tung Michael Untch Celine M Vachon Ans M W van den Ouweland Lizet E van der Kolk Elke M van Veen Elizabeth J vanRensburg Ana Vega Barbara Wappenschmidt Clarice R Weinberg Jeffrey N Weitzel Hans Wildiers Robert Winqvist Alicja Wolk Xiaohong R Yang Drakoulis Yannoukakos Wei Zheng Kristin K Zorn Roger L Milne Peter Kraft Jacques Simard Paul D P Pharoah Kyriaki Michailidou Antonis C Antoniou Marjanka K Schmidt Georgia Chenevix-Trench Douglas F Easton Nilanjan Chatterjee Montserrat García-Closas

Nat Genet 2020 May 18. Epub 2020 May 18.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, USA.

Breast cancer susceptibility variants frequently show heterogeneity in associations by tumor subtype. To identify novel loci, we performed a genome-wide association study including 133,384 breast cancer cases and 113,789 controls, plus 18,908 BRCA1 mutation carriers (9,414 with breast cancer) of European ancestry, using both standard and novel methodologies that account for underlying tumor heterogeneity by estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status and tumor grade. We identified 32 novel susceptibility loci (P < 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41588-020-0609-2DOI Listing

Fertility preservation in patients with mutation.

Ecancermedicalscience 2020 6;14:1033. Epub 2020 May 6.

Breast Cancer Centre, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico.

Evidence suggests a likely negative impact of deleterious mutations on female fertility. Hence, different studies have aimed to address the reproductive potential and performance of fertility preservation strategies in -mutated breast cancer patients with a prime focus on their safety and efficacy. However, several uncertainties exist in many domains of this field. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3332/ecancer.2020.1033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221131PMC

Myeloid-derived suppressor cells in obstetrical and gynecological diseases.

Am J Reprod Immunol 2020 May 17:e13266. Epub 2020 May 17.

Insitute of Obstetrics and Gynecology, Hospital of Obstetrics and Gynecology, Fudan University, Shanghai, 200080, People's Republic of China.

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid-origin cells which have immunosuppressive activities in several conditions, such as cancer and inflammation. Recent research has also associated MDSCs with numerous obstetrical and gynecological diseases. During pregnancy, MDSCs accumulate to ensure maternal-fetal immune tolerance, whereas they are decreased in patients who suffer from early miscarriage or preeclampsia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aji.13266DOI Listing

Higher platelet distribution width is associated with unfavorable prognosis in ovarian cancer.

Cancer Biomark 2020 May 7. Epub 2020 May 7.

Department of Gynaecology and Obstetrics, The Fourth Medical Center, Chinese PLA General Hospital, Beijing, China.

Background: Ovarian cancer (OC) is one of the most malignant gynecological cancers. Platelets play a profound role in cancer growth and metastasis. Platelet distribution width (PDW) is an indicator of platelet activation and is altered in malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-191190DOI Listing

Endometriosis-associated epithelial ovarian cancer: Primary synchronous different cellular type on each ovary.

Taiwan J Obstet Gynecol 2020 May;59(3):460-463

Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan; Female Cancer Foundation, Taipei, Taiwan. Electronic address:

Objective: Endometriosis-associated epithelial ovarian cancer (EOC) is a specific category of EOC, containing either endometrioid or clear cell carcinoma subtype. The characteristic of endometriosis-associated EOC includes an early stage at the diagnosis, presence of single histology type, and better prognosis. The synchronous two subtypes of endometriosis-associated EOC and presentation of far-advanced stage status at the initial diagnosis is rarely reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tjog.2020.03.024DOI Listing

Risk factors associated with epithelial ovarian cancer in women with endometriosis.

Taiwan J Obstet Gynecol 2020 May;59(3):353-355

Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tjog.2020.03.002DOI Listing

Dose-dense chemotherapy: A possible high cost-effectiveness treatment for ovarian cancer.

Taiwan J Obstet Gynecol 2020 May;59(3):351-352

Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Obstetrics and Gynecology, and Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tjog.2020.03.001DOI Listing

MicroRNA-1271-5p inhibits the tumorigenesis of ovarian cancer through targeting E2F5 and negatively regulates the mTOR signaling pathway.

Panminerva Med 2020 May 14. Epub 2020 May 14.

Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Soochow University, The First People's Hospital of Changzhou, Changzhou, China -

Background: MicroRNA-1271-5p (miR-1271-5p) has been reported to participate in the progression of many human cancers. However, the role of miR-1271-5p still remains unclear in ovarian cancer (OC). Therefore, we explored the effect of miR-1271-5p on the development of OC in present study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0031-0808.20.03939-7DOI Listing

NAC1 attenuates BCL6 negative autoregulation and functions as a BCL6 coactivator of FOXQ1 transcription in cancer cells.

Aging (Albany NY) 2020 May 14;12. Epub 2020 May 14.

Department of Toxicology and Cancer Biology, College of Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.

Background: Nucleus accumbens-associated protein 1 (NAC1) has multifaceted roles in cancer pathogenesis and progression, including the development of drug resistance, promotion of cytokinesis, and maintenance of "stem cell-like" phenotypes. NAC1 is a transcriptional co-regulator belonging to the bric-a-brac tramtrack broad (BTB) family of proteins, although it lacks the characteristic DNA binding motif of the BTB family. The formation of higher-order transcription complexes likely depends on its interaction with other DNA-binding co-factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/aging.103203DOI Listing

BNIP3 contributes to cisplatin-induced apoptosis in ovarian cancer cells.

FEBS Open Bio 2020 May 15. Epub 2020 May 15.

Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

BNIP3 is a pro-apoptotic protein that mediates apoptosis, necrosis and autophagy. However, the involvement of BNIP3 in cisplatin-induced apoptosis in ovarian cancer is not clear. In this study, we examined the role of BNIP3 in ovarian cancer during cisplatin treatment and its correlation with clinical outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/2211-5463.12881DOI Listing

Betulinic acid induces apoptosis and impairs migration and invasion in a mouse model of ovarian cancer.

J Food Biochem 2020 May 15:e13278. Epub 2020 May 15.

Department of obstetrics and gynecology, First Affiliated Hospital of Gannan Medical College, Ganzhou, P.R. China.

Betulinic acid (BA) was verified to possess plenty of biological activities including anti-tumor, anti-inflammatory and so on. In our research, we studied the growth inhibition, apoptosis promotion and metastasis resistance of ovarian cancer cells by BA. The result showed that BA showed a time- and dose-dependent inhibitory effect on ovarian cancer cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jfbc.13278DOI Listing

miR-1224-5p inhibits the proliferation and invasion of ovarian cancer via targeting SND1.

Hum Cell 2020 May 14. Epub 2020 May 14.

Department of Obstetrics and Gynecology, China-Japan Union Hospital of Jilin University, Changchun, 130033, Jilin, People's Republic of China.

Emerging evidences have indicated that abnormal expression of microRNAs (miRNAs) contributed to carcinogenesis of ovarian cancer. However, the molecular mechanism of many aberrant expressed miRNAs was not known. Here, we discovered that miR-1224-5p was a downregulated miRNA in ovarian cancer via bioinformatic analysis and RT-qPCR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13577-020-00364-4DOI Listing

Does lymph node ratio have any prognostic significance in maximally cytoreduced node-positive low-grade serous ovarian carcinoma?

Arch Gynecol Obstet 2020 May 14. Epub 2020 May 14.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Ankara, Turkey.

Purpose: To determine the prognostic impact of the lymph node ratio (LNR) in node-positive low-grade serous ovarian cancer (LGSOC).

Methods: We retrospectively reviewed women with LGSOC who had undergone maximal cytoreduction followed by standard chemotherapy in 11 centers from Turkey during a study period of 20 years. Sixty two women with node-positive LGSOC were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-020-05580-9DOI Listing

Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma histotypes.

Sci Rep 2020 May 14;10(1):7946. Epub 2020 May 14.

Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Ovarian cancer comprises multiple subtypes (clear-cell (CCC), endometrioid (EC), high-grade serous (HGSC), low-grade serous (LGSC), and mucinous carcinomas (MC)) with differing molecular and clinical behavior. However, robust histotype-specific biomarkers for clinical use have yet to be identified. Here, we utilized a multi-omics approach to identify novel histotype-specific genetic markers associated with ovarian carcinoma histotypes (CCC, EC, HGSC, and MC) using DNA methylation, DNA copy number alteration and RNA sequencing data for 96 primary invasive early-stage (stage I and II) ovarian carcinomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-64794-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224294PMC
May 2020
5.078 Impact Factor

Age and menopausal status are important factors influencing the serum human epididymis secretory protein 4 level: a prospective cross-sectional study in healthy Chinese people.

Chin Med J (Engl) 2020 May 11. Epub 2020 May 11.

Department of Obstetrics and Gynecology, Center of Gynecologic Oncology, Peking University People's Hospital, Beijing 100044, China.

Background: Human epididymis secretory protein 4 (HE4) is a new ovarian cancer biomarker. The factors influencing HE4 levels are not clear, and the reference data in China are limited. Here, we aim to evaluate the effects of menopause and age on HE4 levels and to provide a possible reference value for HE4 in healthy Chinese people. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CM9.0000000000000785DOI Listing

Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer.

Cancers (Basel) 2020 May 11;12(5). Epub 2020 May 11.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA.

High-grade serous ovarian cancer (HGSOC) remains the most lethal gynecologic cancer in the United States. Genomic analysis revealed roughly half of HGSOC display homologous repair deficiencies. An improved understanding of the genomic and somatic mutations that influence DNA repair led to the development of poly(ADP-ribose) polymerase inhibitors for the treatment of ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12051206DOI Listing

Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes.

Gynecol Oncol 2020 May 10. Epub 2020 May 10.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY, USA.

Objective: To examine trends and associated characteristics and outcomes of minimally invasive surgery (MIS) for women with early-stage ovarian cancer.

Methods: The National Inpatient Sample was queried to examine early-stage ovarian cancer treated with MIS from 2001 to 2011. Annualized hospital surgical volume was defined in the unweighted model as the average number of procedures performed per year in which at least one case was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.04.045DOI Listing

Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway.

Braz J Med Biol Res 2020 8;53(6):e8885. Epub 2020 May 8.

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.

In this study, we aimed to analyze the anti-cancer effects of β-elemene combined with paclitaxel for ovarian cancer. RT-qPCR, MTT assay, western blot, flow cytometry, and immunohistochemistry were used to analyze in vitro and in vivo anti-cancer effects of combined treatment of β-elemene and paclitaxel. The in vitro results showed that β-elemene+paclitaxel treatment markedly inhibited ovarian cancer cell growth, migration, and invasion compared to either paclitaxel or β-elemene treatment alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1414-431x20208885DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228545PMC

Long Noncoding RNA SCAMP1 Targets miR-137/CXCL12 Axis to Boost Cell Invasion and Angiogenesis in Ovarian Cancer.

DNA Cell Biol 2020 May 14. Epub 2020 May 14.

Department of Obstetrics and Gynecology, Xuzhou Central Hospital, Xuzhou, P.R. China.

Ovarian cancer (OC) is one of gynecological malignancies that seriously affects women's health. Mounting evidence demonstrated that long noncoding RNAs (lncRNAs), microRNAs (miRNAs), and messenger RNAs (mRNAs) play important roles in various biological processes related to the pathogenesis of OC. This research aimed to investigate the regulatory mechanism of lncRNA SCAMP1/miR-137/CXCL12 (C-X-C motif chemokine ligand 12) axis on OC progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/dna.2019.5312DOI Listing

Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk.

Arch Med Sci 2020 25;16(3):682-691. Epub 2020 Apr 25.

Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Ji'nan, Shandong, China.

Introduction: Results conflict on the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk, despite wide-ranging investigations. This meta-analysis examines whether the XRCC2 rs3218536 polymorphism is associated with ovarian cancer risk.

Material And Methods: Eligible case-control studies were searched in PubMed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/aoms.2020.94657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212224PMC

Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study.

Clin Cancer Res 2020 May 12. Epub 2020 May 12.

Women's Malignancies Branch, National Cancer Institute

Purpose: Preclinical studies suggest PARP inhibition (PARPi) induces immunostimulatory micromilieu in ovarian cancer thus complementing activity of immune checkpoint blockade. We conducted a phase 2 trial of PARPi olaparib and anti-PD-L1 durvalumab and collected paired fresh core biopsies and blood samples to test this hypothesis.

Experimental Design: In a single-center, proof-of-concept phase 2 study, we enrolled women aged ≥18 with recurrent ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-0056DOI Listing
May 2020
8.722 Impact Factor

Dataset on patients with Recurrent Borderline Ovarian Tumors and Table with Review of Literature on Fertility and Oncologic Outcomes of patients with Borderline Ovarian Tumors.

Data Brief 2020 Jun 30;30:105653. Epub 2020 Apr 30.

Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.

The data presented here is related to the research article entitled "FERTILITY-SPARING SURGERY AND REPRODUCTIVE-OUTCOMES IN PATIENTS WITH BORDERLINE OVARIAN TUMORS" by Plett et al. in Journal of Gynecologic Oncology [1] and is analysed and discussed in detail. 18 Patients with Recurrent Borderline Ovarian Tumors (BOT) were identified and listed in Table 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dib.2020.105653DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206201PMC

Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients.

Cancer Immunol Immunother 2020 May 11. Epub 2020 May 11.

Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, 830-0011, Japan.

Cancer immunotherapy including vaccine therapy is a promising modality for cancer treatment, but few patients show its clinical benefits currently. The identification of biomarkers that can identify patients who will benefit from cancer immunotherapy is thus important. Here, we investigated the potential utility of the circulating cell-free DNA (cfDNA) integrity-a ratio of necrotic cell-derived, longer DNA fragments versus apoptotic cell-derived shorter fragments of Alu gene-as a biomarker of vaccine therapy for patients with ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-020-02599-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222063PMC

Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer.

Cancer Biomark 2020 Apr 30. Epub 2020 Apr 30.

Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.

Background: Epithelial ovarian cancer is a highly lethal gynecological malignancy. Accurate and cost-effective predictive tools to estimate the prognosis of patients with epithelial ovarian cancer before treatment are currently lacking.

Objective: The purpose of this study was to evaluate the prognostic significance of pretreatment serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen-125 (CA-125) in primary epithelial ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-201455DOI Listing

The role systematic lymphadenectomy plays in determining the survival outcome for advanced ovarian cancer patients: a meta- analysis.

Ann Palliat Med 2020 Apr 28. Epub 2020 Apr 28.

Department of Gynecology Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China.

Background: This study aims to evaluate the role systematic lymphadenectomy (SL) p l a y s in advanced ovarian cancer (OC) patients. A meta-analysis was done to compare the progression-free survival (PFS) rates and overall survival (OS) rates between SL and unsystematic lymphadenectomy (USL).

Methods: An extensive literature search from the dates of January 1, 1994, to today was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apm.2020.04.01DOI Listing

Sirtuin1 expression and survival in endometrial and clear-cell uterine cancer.

Histochem Cell Biol 2020 May 9. Epub 2020 May 9.

Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.

Several risk factors like obesity and hyperlipidemia were described for endometrial cancer. Here, the nuclear NAD-dependent histone-deacetylase Sirtuin1 (SIRT1) seems to be important. SIRT1 is also involved in cell regulatory mechanisms and can serve as tumor promotor or suppressor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00418-020-01873-xDOI Listing

p85β regulates autophagic degradation of AXL to activate oncogenic signaling.

Nat Commun 2020 May 8;11(1):2291. Epub 2020 May 8.

School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.

PIK3R2 encodes the p85β regulatory subunit of phosphatidylinositol 3-kinase and is frequently amplified in cancers. The signaling mechanism and therapeutic implication of p85β are poorly understood. Here we report that p85β upregulates the protein level of the receptor tyrosine kinase AXL to induce oncogenic signaling in ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-020-16061-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210311PMC

The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis.

Cell Oncol (Dordr) 2020 May 8. Epub 2020 May 8.

Department of Obstetrics and Gynecology, Shanghai Fengxian District Central Hospital, Southern Medical University, 201499, Shanghai, China.

Purpose: The PI3K/AKT/mTOR pathway is one of the most highly activated cellular signaling pathways in advanced ovarian cancer. Although several PI3K/AKT/mTOR inhibitors have been developed to treat various types of cancer, the antitumor efficacy of many of these compounds against ovarian cancer has remained unclear.

Methods: Here, we tested and compared a panel of 16 PI3K/AKT/mTOR inhibitors (XL765, Miltefosine, Rapamycin, CCI-779, RAD001, FK506, XL147, GSK2110183, IPI-145, GSK2141795, BYL719, GSK458, CAL-101, XL765 analogue SAR245409, Triciribine, and GDC0941) that have entered clinical trials for antitumor activity against ovarian cancer, as well as the front line drug, paclitaxel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13402-020-00514-8DOI Listing

Optimal age for genetic cancer predisposition testing in hereditary Ovarian Cancer Families: How young is too young?

Gynecol Oncol Rep 2020 May 7;32:100569. Epub 2020 Apr 7.

Department of Obstetrics and Gynecology, University of Virginia School of Medicine, Charlottesville, VA, United States.

Small cell carcinoma of the ovary, hypercalcemic type is a rare, aggressive, and typically fatal ovarian cancer that primarily affects young women less than 40 years of age. It is caused by a pathogenic variant in the gene, with nearly half of patients found to have germline pathogenic variants and the remainder demonstrating somatic pathogenic variants. This case report discusses an illustrative case and explores the existing data and potential recommendations to optimize timing of genetic testing in family members, given the presence of a familial germline pathogenic variant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gore.2020.100569DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201186PMC

[Ⅱ.Recent Progress of Treatment Strategy for Recurrent Ovarian Cancers].

Gan To Kagaku Ryoho 2020 Feb;47(2):237-241

Dept. of Obstetrics and Gynecology, National Defense Medical College.

View Article

Download full-text PDF

Source
February 2020

[Ⅰ.Treatment for Primary Ovarian Cancer].

Gan To Kagaku Ryoho 2020 Feb;47(2):233-236

Dept. of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo.

View Article

Download full-text PDF

Source
February 2020

SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway.

J Exp Clin Cancer Res 2020 May 7;39(1):79. Epub 2020 May 7.

Department of Obstetrics and Gynecology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.

Background: The poor prognosis of patients with ovarian cancer is mainly due to cancer progression. γ-Synuclein (SNCG) has reported as a critical player in cancer metastasis. However, its biological roles and mechanism are yet incompletely understood in ovarian cancer, especially in high-grade serous ovarian cancer (HGSOC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-020-01589-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204046PMC